7.06

6.33% 0.42

After Hours: 7.06

Diamedica Therapeutics Inc (DMAC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Diamedica Therapeutics Inc stock is traded at $7.06, with a volume of 409.46K. It is up +6.33% in the last 24 hours and down -0.42% over the past month. DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Previous Close:

$6.64

Open:

$6.65

24h Volume:

409.46K

Relative Volume:

1.04

Market Cap:

$364.92M

Revenue:

Net Income/Loss:

$-19.90M

P/E Ratio:

-13.32

EPS:

-0.53

Net Cash Flow:

$-19.80M

1W Performance:

+1.88%

1M Performance:

-0.42%

6M Performance:

+103.46%

1Y Performance:

+66.12%

1-Day Range:

$6.65

$7.20

1-Week Range:

$6.56

$7.20

52-Week Range:

$3.19

$7.4899

Diamedica Therapeutics Inc Stock (DMAC) Company Profile

Name

Diamedica Therapeutics Inc

Sector

Healthcare (1142)

Industry

Biotechnology (637)

Phone

(763) 496-5454

Address

301 CARLSON PARKWAY, MINNEAPOLIS, MN

Employee

Twitter

@diamedica

Next Earnings Date

2025-03-17

Latest SEC Filings

DMAC's Discussions on Twitter

Compare DMAC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DMAC Diamedica Therapeutics Inc	7.06	343.21M	0	-19.90M	-19.80M	-0.53
VRTX Vertex Pharmaceuticals Inc	407.37	104.55B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	464.95	60.36B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	557.73	59.84B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	799.56	49.07B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	327.03	35.16B	4.56B	-176.77M	225.30M	-1.7177

Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-24	Initiated	H.C. Wainwright	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Jun-22-23	Upgrade	Oppenheimer	Perform → Outperform
Apr-09-21	Initiated	Oppenheimer	Outperform
Feb-17-21	Initiated	ROTH Capital	Buy
Oct-30-20	Initiated	Guggenheim	Buy
Jul-08-20	Initiated	Maxim Group	Buy
Apr-30-19	Initiated	Dougherty & Company	Buy
Mar-05-19	Initiated	Lake Street	Buy

View All

Diamedica Therapeutics Inc Stock (DMAC) Latest News

10:34 AM

How institutional buying supports DiaMedica Therapeutics Inc. stockWatch List & High Accuracy Swing Entry Alerts - newser.com

10:34 AM

05:26 AM

Can DiaMedica Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Fed Impact & Free Community Supported Trade Ideas - newser.com

05:26 AM

Oct 10, 2025

How risky is DiaMedica Therapeutics Inc. stock nowJuly 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com

Oct 10, 2025

Is DiaMedica Therapeutics Inc. stock bottoming outJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com

Oct 10, 2025

How hedge fund analytics apply to DiaMedica Therapeutics Inc. stockEarnings Summary Report & Real-Time Sentiment Analysis - newser.com

Oct 10, 2025

DiaMedica Therapeutics' (DMAC) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat

Oct 10, 2025

Oct 06, 2025

Is it too late to sell DiaMedica Therapeutics Inc.July 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com

Oct 06, 2025

Can DiaMedica Therapeutics Inc. stock continue upward trendJuly 2025 Update & Low Drawdown Trading Techniques - newser.com

Oct 06, 2025

Oct 05, 2025

After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright - MSN

Oct 05, 2025

Oct 04, 2025

Is DiaMedica Therapeutics Inc a good long term investmentHealthcare Stock Analysis & Superior Capital Growth - earlytimes.in

Oct 04, 2025

DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Oct 04, 2025

Oct 03, 2025

Will DiaMedica Therapeutics Inc. bounce back from current support2025 Market Overview & High Accuracy Swing Entry Alerts - newser.com

Oct 03, 2025

DiaMedica Therapeutics Inc. stock volume spike explainedRate Cut & Daily Profit Maximizing Trade Tips - newser.com

Oct 03, 2025

Published on: 2025-10-03 00:24:41 - newser.com

Oct 03, 2025

Oct 02, 2025

Published on: 2025-10-02 18:46:41 - newser.com

Oct 02, 2025

Perigon Wealth Management LLC Acquires Shares of 53,000 DiaMedica Therapeutics, Inc. $DMAC - MarketBeat

Oct 02, 2025

Oct 01, 2025

Tick level data insight on DiaMedica Therapeutics Inc. volatilityJuly 2025 News Drivers & Verified Swing Trading Watchlist - newser.com

Oct 01, 2025

Sep 29, 2025

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Sep 29, 2025

Published on: 2025-09-29 10:18:49 - newser.com

Sep 29, 2025

Sep 27, 2025

What analysts say about DiaMedica Therapeutics Inc stockContrarian Investment Ideas & Free Superior Stock Performance - Early Times

Sep 27, 2025

How DiaMedica Therapeutics Inc. stock reacts to oil prices2025 Winners & Losers & Daily Growth Stock Investment Tips - newser.com

Sep 27, 2025